Safety and tolerability of fixed-dose irbesartanhydrochlorothiazide for rapid control of severe hypertension

Clinical and Experimental Hypertension

Volumn 31, Issue 7, 2009, Pages 572-584

  Neutel, Joel M ^a   Franklin, Stanley S ^b   Bhaumik, Amitabha ^c   Lapuerta, Pablo ^c   Oparil, Suzanne ^d  

^a Orange County Research Center   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Angiotensin receptor blocker (ARB); Fixed dose combination; Irbesartan HCTZ; Severe hypertension

Indexed keywords

HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; IRBESARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BLOOD SAMPLING; BRONCHITIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; INCIDENCE; IRRITABLE COLON; KIDNEY ARTERY STENOSIS; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; ORTHOSTATIC BLOOD PRESSURE; POTASSIUM BLOOD LEVEL; PROSPECTIVE STUDY; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SYNCOPE; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SODIUM CHLORIDE SYMPORTER INHIBITORS; TETRAZOLES; YOUNG ADULT;

EID: 70449358727     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641960902929420     Document Type: Article

References (41)

1. Preston RA, Baltodano NM, Cienki J, Materson BJ. Clinical presentation and management of patients with uncontrolled, severe hypertension: Results from a public teaching hospital. J Hum Hypertens 1999;13:249-255.
2. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007; 49:69-75.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green L A, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252.
4. After the diagnosis: Adherence and persistence with hypertension therapy. Am J Manag Care 2005;11(supp 13):S395-S399.
5. Burnier M, Hess B, Greminger P, Waeber B. Determinants of persistence in hypertensive patients treated with irbesartan: Results of a postmarketing survey. BMC Cardiovasc Disord 2005;5:13.
6. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard,R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-1187. (Pubitemid 46924065)
7. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care 2007;30(suppl 1):S4-S41.
8. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983-1992.
9. Benedict CR. Safe and effective management of hypertension with fixed-dose combination therapy: Focus on losartan plus hydrochlorothiazide. Int J Clin Pract 2000;54:48-54.
10. Chrysant SG. Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan/HCT). Expert Rev Cardiovasc Ther 2003;1:335-343.
11. Croom KF, Curran MP, Goa KL, Perry CM. Irbesartan: A review of its use in hypertension and in the management of diabetic nephropathy. Drugs 2004;64:999-1028.
12. Bohm M, Sachse A. Safety and tolerability of eprosartan in combination with hydrochlorothiazide. Drug Saf. 2002;25:599-611.
13. Maillard M, Burnier M. Telmisartan/hydrochlorothiazide: A new fixed dose combination. Expert Rev Cardiovasc Ther 2005;3:375-386.
14. Melian EB, Jarvis B. Candesartan cilexetil plus hydrochlorothiazide combination: A review of its use in hypertension. Drugs 2002;62:787-816.
15. Chrysant SG, Chrysant GS. Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Opin Pharmacother 2004;5:657-667.
16. Waeber B. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. Expert Rev Cardiovasc Ther 2003;1:43-50.
17. Neutel JM, Franklin SS, Oparil S, Bhaumik A, Ptaszynska A, Lapuerta P. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens (Greenwich) 2006;8:850-857; quiz 858-859.
18. Coca A, Calvo C, Sobrino J Gomez E, Lopez-Paz JE., Sierra C, Bragulat E, de la Sierra A. Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension. Clin Ther 2003;25:2849-2864.
19. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L., et al. and the VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004;363:2022-2031.
20. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al and the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: Blood pressure measurement in humans: A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005;45:142-161. (Pubitemid 40066429)
21. Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC, Ofili,EO, et al. and the INCLUSIVE Investigators. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: The INCLUSIVE trial. J Clin Hypertens (Greenwich) 2005;7:578-586.
22. Howe P, Phillips P, Saini R, Kassler-Taub K. The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group. Clin Exp Hypertens 1999;21:1373-1396.
23. Franklin SS, Bhaumik A, Ptaszynska A. Early reduction of exposure to severe blood pressure levels with irbesartan/HCTZ as a first-line treatment of severe hypertension. In: European Society of Hypertension/European Society of Cardiology, Madrid, Spain, June 12-16, 2006, Poster 492.
24. Kochar M, Guthrie R, Triscari J, Kassler-Taub K, Reeves RA. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999;12:797-805.
25. Raskin P, Guthrie R, Flack J, Reeves R, Saini R. The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide. J Hum Hypertens 1999;13:683-687.
26. Rosenstock J, Rossi L, Lin CS, MacNeil D, Osbakken M. The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone. J Clin Pharm Ther 1998;23:433-440.
27. Meredith PA. Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: Potential benefits beyond the antihypertensive effect. Am J Cardiovasc Drugs 2005;5:171-183.
28. Sowers JR, Neutel JM, Saunders E, et al., and the INCLUSIVE Investigators. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich) 2006;8:470-480.
29. Ofili EO, Ferdinand KC, Saunders E, Neutel JM, Bakris G L, Cushman WC, et al. Irbesartan/ HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. J Natl Med Assoc 2006;98:618-626.
30. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ 2003;326:1427.
31. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: The cycle repeats. Drugs 2002;62:443-462.
32. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-1053.
33. Bonner G, Fuchs W. Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension. Curr Med Res Opin 2004;20:597-602.
34. Oparil S, Aurup P, Snavely D, Goldberg A. Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension. Am J Cardiol 2001;87:721-726.
35. Dunlay MC, Fitzpatrick V, Chrysant S, Francischetti EA, Goldberg AI, Sweet CS. Losartan potassium as initial therapy in patients with severe hypertension. J Hum Hypertens 1995; 9:861-867.
36. Neutel JM, Smith DH, Reilly PA. The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension. Int J Clin Pract 1999;53:175-178.
37. Cifkova R, Peleska J, Hradec J, Rosolova H, Pinterova E, Zeman K, et al. Valsartan and atenolol in patients with severe essential hypertension. J Hum Hypertens 1998;12:563-567.
38. Oparil S, Levine JH, Zuschke CA, Gradman AH, Ripley E, Jones DW, et al. Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators. Am J Cardiol 1999;84:289-293.
39. Sega R. Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group. Blood Press 1999;8:114-121.
40. Salerno CM, Demopoulos L, Mukherjee R, Gradman AH. Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension. J Clin Hypertens (Greenwich) 2004;6:614-620.
41. Flanigan JS, Vitberg D. Hypertensive emergency and severe hypertension: What to treat, who to treat, and how to treat. Med Clin North Am 2006;90:439-451.